



CLAIMS

1. A compound having the structure of Formula (A) or a pharmaceutically acceptable salt thereof:



Formula (A)

wherein:



L is -CH₂- or -CH₂CH₂-;


Y₁ is -CH₂- or -CH₂CH₂-;

Y₂ is -CH₂- or -CH₂CH₂-;

Y₃ is -CH₂- , -XCH₂- or -CH₂X-;

X is -CH₂- or O;

R¹ is -NHC(=O)R⁶, -NHC(=O)(CH₂)_nR⁶, -NH(CH₂)_nC(=O)R⁶, -NHC(=O)(CH₂)_mNHR⁵, -NHC(=O)(CH₂)_mN(R⁵)₂, -NHC(=O)(CHR⁹)_mNHR⁵, -NHC(=O)(CH₂)_mNH₂, -NHC(=O)(CH₂)_nOR⁹, -NHC(=O)OR⁹, -NH(CH₂)_mC(=O)N(R⁵)₂, -

$\text{NH}(\text{CHR}^9)_n\text{C}(=\text{O})\text{R}^6$, $\text{NHC}(=\text{O})(\text{CHR}^9)_n\text{R}^6$, $-\text{NHC}(=\text{O})(\text{CHR}^9)_n\text{N}(\text{R}^8)_2$, -
 $\text{NHC}(=\text{O})(\text{CHR}^9)_n\text{NHR}^8$, $-\text{NH}(\text{CHR}^9)_n\text{C}(=\text{O})\text{N}(\text{R}^8)_2$, $-\text{NH}(\text{CHR}^9)_m\text{C}(=\text{O})\text{R}^6$, $-\text{NHR}^6$, -
 NR^5R^6 , $-\text{NH}_2$, $-\text{N}(\text{R}^5)_2$, $-\text{NHR}^5$, $-\text{NHR}^8$, $-\text{N}(\text{R}^6\text{R}^8)$, $-\text{NH}(\text{C}(\text{R}^9)_2)_n\text{R}^{10}$, $-\text{NR}^9\text{C}(=\text{O})\text{OR}^{11}$,
 $-\text{NH}(\text{CH}_2)_n\text{R}^6$, $-\text{NH}(\text{CHR}^9)_n\text{R}^6$, $-\text{N}(\text{R}^6)_2$, $-\text{NHC}(=\text{O})(\text{CH}_2)_n\text{N}(\text{CD}_3)_2$, -
 $\text{NH}(\text{CHR}^9)_n\text{CH}_2\text{OR}^9$, $-\text{NHCH}_2(\text{CHR}^9)_n\text{OR}^9$, $-\text{NH}(\text{CHR}^9)_n\text{OR}^9$, $-\text{NR}^9(\text{CH}_2)_n\text{OR}^9$, -
 $\text{NHCH}_2(\text{C}(\text{R}^9)_2)_n\text{OR}^9$, $-\text{OR}^9$, $-\text{NR}^9\text{C}(=\text{O})\text{R}^5$, $-\text{NR}^9\text{C}(=\text{O})(\text{CH}_2)_n\text{R}^5$, $-\text{NR}^9\text{C}(=\text{O})\text{OR}^5$, -
 $\text{NHS}(=\text{O})_2\text{R}^5$, $-\text{NHC}(=\text{O})(\text{CH}_2)_n\text{NR}^9\text{C}(=\text{O})\text{R}^5$, $-\text{NHC}(=\text{O})(\text{CH}_2)_n\text{NR}^9\text{S}(=\text{O})_2\text{R}^5$,

, an 8-oxa-3-azabicyclo[3.2.1]octanyl, a 5-6 membered
heteroaryl having 1 to 3 ring members independently selected from N, O and S, or a
4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected
from N, NH, NR^{16} and O which is unsubstituted or is substituted with 1-2 R^7 groups;
 R^2 is H, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl or $\text{C}_1\text{-C}_6$ alkyl substituted with 1-2 R^{15} groups;
 R^3 is H, $\text{C}_1\text{-C}_6$ alkyl, $-\text{CD}_3$ or benzyl substituted with 1-2 R^{10} groups;
 R^4 is H, NH_2 , $\text{C}_1\text{-C}_6$ alkyl, halo or a phenyl substituted with 0-2 R^{18} groups;
each R^5 is independently selected from $\text{C}_1\text{-C}_6$ alkyl, $-\text{CD}_3$ and $-(\text{CH}_2)_n\text{OR}^9$;
 R^6 is a $\text{C}_3\text{-C}_6$ cycloalkyl, an 8-oxa-3-azabicyclo[3.2.1]octane or a 4-6 membered
heterocycloalkyl having 1 to 2 ring members independently selected from N, NH,
 NR^{16} and O which is unsubstituted or is substituted with 1-2 R^{12} groups;
each R^7 is independently selected from $\text{C}_1\text{-C}_6$ alkyl, halo, hydroxyl, oxo and a $\text{C}_1\text{-C}_6$ alkyl
substituted with 1 to 3 $-\text{OH}$;
each R^8 is independently selected from $\text{C}_1\text{-C}_6$ haloalkyl, $-(\text{C}(\text{R}^9)_2)_n\text{OR}^9$ and a $\text{C}_1\text{-C}_6$ alkyl
substituted with 1 to 3 $-\text{OH}$;
each R^9 is independently selected from H and $\text{C}_1\text{-C}_6$ alkyl;
 R^{10} is $\text{C}_1\text{-C}_6$ alkoxy or $\text{C}_3\text{-C}_6$ cycloalkyl;
 R^{11} is a $\text{C}_3\text{-C}_6$ cycloalkyl which is unsubstituted or is substituted with 1 to 3 $\text{C}_1\text{-C}_6$ alkyl
groups;
each R^{12} is independently selected from $\text{C}_1\text{-C}_6$ alkyl, hydroxyl, halo and a $\text{C}_1\text{-C}_6$ alkyl
substituted with 1 to 3 $-\text{OH}$;
 R^{13} is H or $\text{C}_1\text{-C}_6$ alkyl;
 R^{14} is H or $\text{C}_1\text{-C}_6$ alkyl;
 R^{15} is $-\text{NHC}(=\text{O})(\text{CH}_2)_m\text{NHR}^5$, $-\text{NHC}(=\text{O})(\text{CH}_2)_m\text{N}(\text{R}^5)_2$, $-\text{NHC}(=\text{O})(\text{CH}_2)_m\text{NH}_2$, -
 $\text{NHC}(=\text{O})(\text{CHR}^9)_n\text{R}^6$, $-\text{NHC}(=\text{O})(\text{CHR}^9)_n\text{N}(\text{R}^8)_2$, $-\text{NHC}(=\text{O})(\text{CHR}^9)_n\text{NHR}^8$, -
 $\text{NH}(\text{CHR}^9)_n\text{C}(=\text{O})\text{N}(\text{R}^8)_2$, $-\text{NH}(\text{CHR}^9)_n\text{C}(=\text{O})\text{R}^6$, $-\text{NHR}^6$, $-\text{NH}_2$, $-\text{N}(\text{R}^5)_2$, $-\text{NHR}^8$, -

$N(R^6R^8)$, $-NH(C(R^9)_2)_nR^{10}$, $-NR^9C(=O)OR^{11}$, $-NH(CHR^9)_nR^6$, $-N(R^6)_2$, $-N(CD_3)_2$, $-NH(CHR^9)_nOR^9$ or $-NHCH_2(C(R^9)_2)_nOR^9$;

each R^{16} is C_1 - C_6 alkyl;


each R^{17} is independently selected from H and C_1 - C_6 alkyl;

each R^{18} is independently selected from halo, $-CN$, C_1 - C_6 alkoxy and C_1 - C_6 alkyl;


m is 1, 2, 3, 4, 5 or 6, and

n is 1, 2, 3, 4, 5 or 6.

2. The compound of claim 1 having the structure of Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof:




Formula (I)




Formula (II),

wherein Y_1 , Y_2 , Y_3 , L , R^1 , R^2 and R_A are as defined in claim 1.


3. The compound of claim 1, wherein the compound of Formula (A) has the structure of Formula (Ia), Formula (Ib), Formula (Ic), Formula (Id), Formula (Ie), Formula (If), Formula (Ig), Formula (Ih), Formula (Ii), Formula (Ij), Formula (Ik), Formula (IIa), Formula (IIb), Formula (IIc), Formula (IId), Formula (IIe), Formula (IIf), Formula (IIg), Formula (IIh), Formula (IIi), Formula (IIj) or Formula (IIk), or a pharmaceutically acceptable salt thereof:




Formula (Ia)




Formula (Ib)




Formula (Ic)




Formula (Id)




Formula (Ie)




Formula (If)




Formula (Ig)




Formula (Ih)




Formula (Ii)




Formula (Ij)




Formula (Ik)




Formula (IIa)




Formula (IIb)




Formula (IIc)




Formula (IId)




Formula (IIe)




Formula (IIf)




Formula (IIg)




Formula (IIh)



Formula (IIi)



Formula (IIj)



Formula (IIk)

wherein Y₁, Y₂, Y₃, L, R¹, R², R³, R⁴, R¹⁸, R¹³ and R¹⁴ are as defined in claim 1.

4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R¹ is -NHC(=O)R⁶, -NHC(=O)(CH₂)_nR⁶, -NH(CH₂)_nC(=O)R⁶, -NHC(=O)(CH₂)_mNHR⁵, -NHC(=O)(CH₂)_mN(R⁵)₂, -NHC(=O)(CHR⁹)_mNHR⁵, -NHC(=O)(CH₂)_mNH₂, -NHC(=O)(CH₂)_nOR⁹, -NHC(=O)OR⁹, -NH(CH₂)_mC(=O)N(R⁵)₂, -NH(CHR⁹)_mC(=O)R⁶, -NHR⁶, -NR⁵R⁶, -NH₂, -N(R⁵)₂, -NHR⁵, -NHR⁸, -NR⁹C(=O)OR¹¹, -NH(CH₂)_nR⁶, -N(R⁶)₂, -NHC(=O)(CH₂)_nN(CD₃)₂, -NH(CHR⁹)_nCH₂OR⁹, -NHCH₂(CHR⁹)_nOR⁹, -NH(CHR⁹)_nOR⁹, -NR⁹(CH₂)_nOR⁹, -NHCH₂(C(R⁹)₂)_nOR⁹, -OR⁹, -NR⁹C(=O)R⁵, -NR⁹C(=O)OR⁵, -NHS(=O)₂R⁵, -NHC(=O)(CH₂)_nNR⁹C(=O)R⁵, or -NHC(=O)(CH₂)_nNR⁹S(=O)₂R⁵.
5. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R¹ is -NHC(=O)R⁶, -NHC(=O)(CH₂)_nR⁶, -NH(CH₂)_nC(=O)R⁶, -NHC(=O)(CH₂)_mNHR⁵, -NHC(=O)(CH₂)_mN(R⁵)₂, -NHC(=O)(CHR⁹)_mNHR⁵, -NHC(=O)(CH₂)_mNH₂, -NH(CH₂)_mC(=O)N(R⁵)₂, -NH(CHR⁹)_nC(=O)R⁶, -NHR⁶, -NH₂, -N(R⁵)₂, -NHR⁵, -NHR⁸, -NH(CHR⁹)_nOR⁹ or -NHCH₂(C(R⁹)₂)_nOR⁹.
6. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R¹ is -NHC(=O)R⁶, -NHC(=O)(CHR⁹)_nR⁶, -NH(CHR⁹)_nC(=O)R⁶ or -NHR⁶.

7. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:

L is $-\text{CH}_2-$ or $-\text{CH}_2\text{CH}_2-$;

Y_1 is $-\text{CH}_2-$ or $-\text{CH}_2\text{CH}_2-$;

Y_2 is $-\text{CH}_2-$ or $-\text{CH}_2\text{CH}_2-$;

Y_3 is $-\text{CH}_2-$ or $-\text{XCH}_2-$;

X is $-\text{CH}_2-$ or O;

R^1 is $-\text{NH}(\text{CH}_2)_n\text{C}(=\text{O})\text{R}^6$, $-\text{NH}(\text{CH}_2)_m\text{C}(=\text{O})\text{N}(\text{R}^5)_2$, $-\text{NH}(\text{CHR}^9)_n\text{C}(=\text{O})\text{R}^6$, $-\text{NH}(\text{CHR}^9)_n\text{C}(=\text{O})\text{N}(\text{R}^8)_2$, $-\text{NH}(\text{CHR}^9)_m\text{C}(=\text{O})\text{R}^6$, $-\text{NH}(\text{C}(\text{R}^9)_2)_n\text{R}^{10}$, $-\text{NH}(\text{CH}_2)_n\text{R}^6$, $-\text{NH}(\text{CHR}^9)_n\text{R}^6$, $-\text{NH}(\text{CHR}^9)_n\text{CH}_2\text{OR}^9$, $-\text{NHCH}_2(\text{CHR}^9)_n\text{OR}^9$, $-\text{NH}(\text{CHR}^9)_n\text{OR}^9$, $-\text{NR}^9(\text{CH}_2)_n\text{OR}^9$, or $-\text{NHCH}_2(\text{C}(\text{R}^9)_2)_n\text{OR}^9$;

R^2 is H, C_1 - C_6 alkyl or C_1 - C_6 haloalkyl;

R^3 is H, C_1 - C_6 alkyl or $-\text{CD}_3$;

R^4 is H, NH_2 , C_1 - C_6 alkyl or halo;

each R^5 is independently C_1 - C_6 alkyl, $-\text{CD}_3$ or $-(\text{CH}_2)_n\text{OR}^9$;

R^6 is a C_3 - C_6 cycloalkyl or a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR^{16} and O which is unsubstituted or is substituted with 1-2 R^{12} groups;

each R^8 is independently selected from C_1 - C_6 haloalkyl, $-(\text{C}(\text{R}^9)_2)_n\text{OR}^9$ and a C_1 - C_6 alkyl substituted with 1 to 3 $-\text{OH}$;

each R^9 is independently selected from H and C_1 - C_6 alkyl;

R^{10} is C_1 - C_6 alkoxy or C_3 - C_6 cycloalkyl;

each R^{12} is independently selected from C_1 - C_6 alkyl, hydroxyl, halo and a C_1 - C_6 alkyl substituted with 1 to 3 $-\text{OH}$;

R^{13} is H or C_1 - C_6 alkyl;

R^{14} is H or C_1 - C_6 alkyl;

each R^{16} is C_1 - C_6 alkyl;

each R^{17} is independently H or C_1 - C_6 alkyl;

each R^{18} is independently halo, $-\text{CN}$, C_1 - C_6 alkoxy or C_1 - C_6 alkyl;

m is 1, 2, 3, 4, 5 or 6, and

n is 1, 2, 3, 4, 5 or 6.

8. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:

L is $-\text{CH}_2-$ or $-\text{CH}_2\text{CH}_2-$;

Y_1 is $-\text{CH}_2-$ or $-\text{CH}_2\text{CH}_2-$;

Y_2 is $-CH_2-$ or $-CH_2CH_2-$;

Y_3 is $-CH_2-$ or $-XCH_2-$;

X is $-CH_2-$ or O ;

R^1 is $-NHR^6$, $-NR^5R^6$, $-NH_2$, $-N(R^5)_2$, $-NHR^5$, $-NHR^8$, $-N(R^6R^8)$ or $-N(R^6)_2$;

R^2 is H , C_1-C_6 alkyl or C_1-C_6 haloalkyl;

R^3 is H , C_1-C_6 alkyl or $-CD_3$;

R^4 is H , NH_2 , C_1-C_6 alkyl or halo;

each R^5 is independently C_1-C_6 alkyl, $-CD_3$ or $-(CH_2)_nOR^9$;

R^6 is a C_3-C_6 cycloalkyl or a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N , NH , NR^{16} and O which is unsubstituted or is substituted with 1-2 R^{12} groups;

each R^8 is independently selected from C_1-C_6 haloalkyl, $-(C(R^9)_2)_nOR^9$ and a C_1-C_6 alkyl substituted with 1 to 3 $-OH$;

each R^{12} is independently selected from C_1-C_6 alkyl, hydroxyl, halo and a C_1-C_6 alkyl substituted with 1 to 3 $-OH$;

R^{13} is H or C_1-C_6 alkyl;

R^{14} is H or C_1-C_6 alkyl;

each R^{16} is C_1-C_6 alkyl;

each R^{17} is independently H or C_1-C_6 alkyl;

each R^{18} is independently halo, $-CN$, C_1-C_6 alkoxy or C_1-C_6 alkyl;

m is 1, 2, 3, 4, 5 or 6, and

n is 1, 2, 3, 4, 5 or 6.

9. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^6 is a unsubstituted 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N , NH and O .
10. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^6 is cyclobutyl, oxetanyl, piperidinyl, pyrrolidinyl, morpholinyl or azetadinyl.
11. The compound of claim 1 selected from:

4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;

4-((3-methyl-5-(6-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;

4-((3-methyl-5-(2-methyl-1,7-naphthyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;

4-((3-methyl-5-(2-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;

4-((5-(1,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;

N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)oxetan-3-amine;

N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(dimethylamino)acetamide

(S)-N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide;

(R)-N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide;

6-(4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-oxa-6-azaspiro[3.3]heptane;

4-(1-((4-aminobicyclo[2.2.2]octan-1-yl)methyl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-amine;

4-(2-((4-aminobicyclo[2.2.2]octan-1-yl)methyl)-6,7-dihydro-2H-pyrazolo[4,3-c]pyridin-5(4H)-yl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-amine;

4-(1-((4-aminobicyclo[2.2.2]octan-1-yl)methyl)-3-methyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-amine;

4-(2-((4-aminobicyclo[2.2.2]octan-1-yl)methyl)-3-methyl-6,7-dihydro-2H-pyrazolo[4,3-c]pyridin-5(4H)-yl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-amine;

4-((5-(5-chloro-1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;

1,6-dimethyl-4-(3-methyl-1-((4-(pyrrolidin-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)-1H-pyrazolo[3,4-d]pyrimidine;

1,3,5-trimethyl-7-(3-methyl-1-((4-(pyrrolidin-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)-1H-pyrazolo[4,3-d]pyrimidine;

N-(2-methoxyethyl)-4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;

4-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine;

2-(ethylamino)-N-(4-((3-methyl-5-(6-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)acetamide;

4-(4-((3-methyl-5-(6-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine;

2-(ethylamino)-N-(4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)acetamide;

4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-(oxetan-3-ylmethyl)bicyclo[2.2.2]octan-1-amine;

3-(dimethylamino)-N-(4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)propanamide;

4-(4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine;

4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;

N-cyclobutyl-4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;

N,N-dicyclobutyl-4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;

6-methyl-4-(3-methyl-1-((4-(piperidin-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)-1H-pyrazolo[3,4-d]pyrimidine;

6-methyl-4-(3-methyl-1-((4-(pyrrolidin-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)-1H-pyrazolo[3,4-d]pyrimidine;

(3-(((4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)amino)methyl)oxetan-3-yl)methanol;

N-(4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)azetidine-3-carboxamide;

(S)-N-(4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide;

(S)-N-(4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-2-carboxamide;

(R)-N-(4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide;

(R)-N-(4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-2-carboxamide;

3,6-dimethyl-4-(3-methyl-1-((4-morpholinobicyclo[2.2.2]octan-1-yl)methyl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)isoxazolo[5,4-d]pyrimidine;

1,3,5-trimethyl-7-(3-methyl-1-((4-(piperidin-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)-1H-pyrazolo[3,4-d]pyrimidine;

1,6-dimethyl-4-(3-methyl-1-((4-(piperidin-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)-1H-pyrazolo[3,4-d]pyrimidine;

4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N,N-bis(trideuteromethyl)bicyclo[2.2.2]octan-1-amine;

4-((3-methyl-5-(1H-pyrazolo[3,4-b]pyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;

4-((3-methyl-5-(1H-pyrazolo[3,4-b]pyridin-4-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl)methyl)bicyclo[2.2.2]octan-1-amine;

4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N,N-dimethylbicyclo[2.2.2]octan-1-amine;

4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.1]heptan-1-amine;

4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;

4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-ol;

N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)acetamide;

N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)methanesulfonamide;

tert-butyl 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)(methyl)carbamate;

4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-methylbicyclo[2.2.2]octan-1-amine;

1-methylcyclopropyl 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)(methyl)carbamate;

3-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl)methyl)bicyclo[1.1.1]pentan-1-amine;

4-((5-(1-(4-methoxybenzyl)-6-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;

N-cyclobutyl-4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;

4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-isopropylbicyclo[2.2.2]octan-1-amine;

2-((4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)amino)propan-1-ol;

4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-ethylbicyclo[2.2.2]octan-1-amine;

5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-1-((4-(pyrrolidin-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;

4-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine;

4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-7,7-dimethyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;

N-(2,2-difluoroethyl)-4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;

-((3-methyl-5-(2-methylquinolin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;

4-((3-methyl-5-(2-phenylpyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;

1-((4-(azetidin-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;

4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-7,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl)methyl)bicyclo[2.2.2]octan-1-amine;

4-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)thiomorpholine 1,1-dioxide;

5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-1-((4-(piperidin-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;

1-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)azetidin-3-ol;

4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-(2-methoxyethyl)bicyclo[2.2.2]octan-1-amine;

4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N,N-bis(2-methoxyethyl)bicyclo[2.2.2]octan-1-amine;

4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-(2-ethoxyethyl)bicyclo[2.2.2]octan-1-amine;

4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N,N-bis(2-ethoxyethyl)bicyclo[2.2.2]octan-1-amine;

4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-(2-methoxyethyl)-N-methylbicyclo[2.2.2]octan-1-amine;

(3S,4R)-1-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)pyrrolidine-3,4-diol;

(S)-1-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)pyrrolidin-3-ol;

2-((4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)amino)-N,N-dimethylacetamide;

N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-N-methyloxetan-3-amine;

4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-isopropyl-N-methylbicyclo[2.2.2]octan-1-amine;

N-cyclobutyl-4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-methylbicyclo[2.2.2]octan-1-amine;

(3S,4S)-1-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)pyrrolidine-3,4-diol;

1-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-2-oxabicyclo[2.2.2]octan-4-amine;

5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-1-((4-(pyrrolidin-1-yl)-2-oxabicyclo[2.2.2]octan-1-yl)methyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;

4-((5-(6-(4-fluorophenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;

4-(4-(1-((4-aminobicyclo[2.2.2]octan-1-yl)methyl)-3-methyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)pyridin-2-yl)benzonitrile;

3-methyl-5-(2-phenylpyridin-4-yl)-1-((4-(pyrrolidin-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;

2-methyl-4-(3-methyl-1-((4-(pyrrolidin-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)-1,7-naphthyridine;

4-((5-(2-(4-fluorophenyl)pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;

4-((5-(2-(2-fluoro-4-methylphenyl)pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;

4-((5-(2-(4-methoxyphenyl)pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;

4-((3-methyl-5-(2-(p-tolyl)pyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;

4-(2-(5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)ethyl)bicyclo[2.2.2]octan-1-amine;

4-((5-(2,8-dimethyl-1,7-naphthyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;

4-((3-methyl-5-(2-methyl-6-phenylpyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;

4-((5-([2,2'-bipyridin]-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;

5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-1-((4-(piperidin-1-yl)-2-oxabicyclo[2.2.2]octan-1-yl)methyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;

4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-(1-methoxypropan-2-yl)bicyclo[2.2.2]octan-1-amine;

4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-ethyl-N-methylbicyclo[2.2.2]octan-1-amine;

1-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N,N-dimethyl-2-oxabicyclo[2.2.2]octan-4-amine;

2-((4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)amino)-1-(piperidin-1-yl)ethanone;

N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(pyrrolidin-1-yl)acetamide;

4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-(2-methoxy-2-methylpropyl)bicyclo[2.2.2]octan-1-amine;

1-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-(2-methoxyethyl)-2-oxabicyclo[2.2.2]octan-4-amine;

4-((5-(2-chloro-5,7-dihydrofuro[3,4-d]pyrimidin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;

4-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-1-methylpiperazin-2-one;

N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-3-(dimethylamino)propanamide;

2-((4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)amino)-1-(pyrrolidin-1-yl)ethanone;

(R)-4-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-methylmorpholine;

1-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-4-methylpiperazin-2-one;

(S)-4-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-methylmorpholine;

(2S,6R)-4-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2,6-dimethylmorpholine;

(2S,6S)-4-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2,6-dimethylmorpholine;

N-(cyclobutylmethyl)-1-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-2-oxabicyclo[2.2.2]octan-4-amine;

(2R,6R)-4-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2,6-dimethylmorpholine;

N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(ethylamino)acetamide;

3-amino-N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)propanamide;

6-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-oxa-6-azaspiro[3.3]heptane;

(R)-N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(methylamino)propanamide;

(S)-N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(methylamino)propanamide;

1-((4-(1H-imidazol-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;

(1R,5S)-3-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-8-oxa-3-azabicyclo[3.2.1]octane;

N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(methylamino)acetamide;

N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-4-methylmorpholine-3-carboxamide;

1-((4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)amino)-2-methylpropan-2-ol;

2-(ethylamino)-N-(4-((3-methyl-5-(5-methyl-1H-pyrazolo[4,3-b]pyridin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)acetamide;

N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-2-carboxamide;

N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-3-(ethylamino)propanamide;

N-ethyl-4-((3-methyl-5-(2-phenylpyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;

(S)-4-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-3-methylmorpholine;

(R)-4-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-3-methylmorpholine;

N-(2-methoxyethyl)-4-((3-methyl-5-(2-phenylpyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;

N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)azetidine-3-carboxamide;

N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(ethyl(methyl)amino)acetamide;

N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(3-fluoroazetidin-1-yl)acetamide;

2-(bis(trideuteromethyl)amino)-N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)acetamide;

N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-hydroxyacetamide;

N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(3-hydroxyazetidin-1-yl)acetamide;

(3-(((4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)amino)methyl)oxetan-3-yl)methanol;

N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(N-methylmethylsulfonamido)acetamide;

N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(N-methylacetamido)acetamide

4-((3-methyl-5-(6-methyl-1-(trideuteromethyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;

(S)-N-(4-((5-(1-ethyl-6-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide;

N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-3-(methylamino)propanamide;

N-cyclobutyl-1-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-2-oxabicyclo[2.2.2]octan-4-amine;

N-cyclobutyl-4-((3-methyl-5-(2-phenylpyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;

tert-butyl 4-((5-(1-ethyl-6-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate;

tert-butyl (4-((3-methyl-5-(2-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate;
 tert-butyl (4-((3-methyl-5-(2-methyl-1,7-naphthyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate;
 tert-butyl (4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.1]heptan-1-yl)carbamate;
 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine, and
 4-((5-(1-ethyl-6-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine.

12. The compound of claim 1 selected from:

N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)oxetan-3-amine;
 N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(dimethylamino)acetamide;
 (S)-N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide;
 (R)-N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide, and
 6-(4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-oxa-6-azaspiro[3.3]heptane.

13. A pharmaceutical composition comprising a therapeutically effective amount a compound of a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
14. Use of a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for inhibiting activity of an endosomal Toll-Like Receptor selected from TLR7, TLR8 and TLR9, or a combination thereof,.

15. Use of a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for inhibiting activity of an endosomal Toll-Like Receptor pathway selected from TLR7 pathway, TLR8 pathway and TLR9 pathway, or a combination thereof,.
16. Use of a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating an autoimmune disease associated with
 - i) TLR7 activity, or
 - ii) TLR7 activity and TLR8 activity, or
 - iii) TLR7 activity and TLR8 activity and TLR9 activity,
 wherein the autoimmune disease is systemic lupus erythematosus, cutaneous lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
17. A combination comprising a therapeutically effect amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, and one or more additional therapeutic agents, wherein the additional therapeutic agent is independently selected from anti-inflammatory agents, immunomodulatory agents, immunosuppressive agents, cytokines, nonsteroidal anti-inflammatory drugs (NSAIDs), antimalarial compounds, anti-rheumatic compounds, inhibitors of B-cell activating factor (BAFF), inhibitors of B-lymphocyte stimulator (BLyS), and steroid hormones.
18. The compound of Formula (Ia) of claim 3, or a pharmaceutically acceptable salt thereof, wherein:

L is -CH₂-;

Y₁ is -CH₂CH₂-;

Y₂ is -CH₂CH₂-;

Y₃ is -XCH₂-;

X is -CH₂-;

R¹ is -NHC(=O)R⁶;

R² is C₁-C₆alkyl;


R³ is C₁-C₆alkyl;

R^4 is C_1 - C_6 alkyl;


R^6 is an unsubstituted 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, and O; and

R^{14} is H.


19. The compound of claim 18, or a pharmaceutically acceptable salt thereof, wherein the compound is




(S)-N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide;



(S)-N-(4-((5-(1-ethyl-6-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide;




N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)azetidine-3-carboxamide;



N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-2-carboxamide;

or



(R)-N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide.

20. A pharmaceutical composition comprising a therapeutically effective amount a compound of claim 18, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
21. Use of a therapeutically effective amount of a compound of claim 18, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating an autoimmune disease associated with the activity of an endosomal Toll-Like Receptor selected from TLR7, TLR8 and TLR9, or a combination thereof, wherein the autoimmune disease is systemic lupus erythematosus, cutaneous lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
22. Use of a therapeutically effective amount of a compound of claim 18, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating an autoimmune disease associated with the activity of an endosomal Toll-Like Receptor pathway selected from TLR7 pathway, TLR8 pathway and TLR9 pathway, or a combination thereof, wherein the autoimmune disease is systemic lupus erythematosus, cutaneous lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
23. Use of a therapeutically effective amount of a compound of claim 18, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating an autoimmune disease associated with
 - i) TLR7 activity, or
 - ii) TLR7 activity and TLR8 activity, or
 - iii) TLR7 activity and TLR8 activity and TLR9 activity,

wherein the autoimmune disease is systemic lupus erythematosus, cutaneous lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.

24. A combination comprising a therapeutically effect amount of a compound of claim 18, or a pharmaceutically acceptable salt thereof, and one or more additional therapeutic agents, wherein the additional therapeutic agent is independently selected from anti-inflammatory agents, immunomodulatory agents, immunosuppressive agents, cytokines, nonsteroidal anti-inflammatory drugs (NSAIDs), antimalarial compounds, anti-rheumatic compounds, inhibitors of B-cell activating factor (BAFF), inhibitors of B-lymphocyte stimulator (BLyS), and steroid hormones.
25. A compound, which is (S)-N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide.
26. A pharmaceutical composition comprising a therapeutically effective amount a compound of claim 25, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
27. A combination comprising a therapeutically effect amount of the compound of claim 25, or a pharmaceutically acceptable salt thereof, and one or more additional therapeutic agents, wherein the additional therapeutic agent is independently selected from anti-inflammatory agents, immunomodulatory agents, immunosuppressive agents, cytokines, nonsteroidal anti-inflammatory drugs (NSAIDs), antimalarial compounds, anti-rheumatic compounds, inhibitors of B-cell activating factor (BAFF), inhibitors of B-lymphocyte stimulator (BLyS), and steroid hormones.
28. Use of a therapeutically effective amount of the compound of claim 25, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for inhibiting activity of an endosomal Toll-Like Receptor selected from TLR7, TLR8 and TLR9, or a combination thereof.
29. Use of a therapeutically effective amount of the compound of claim 25, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for inhibiting activity of an endosomal Toll-Like Receptor pathway selected from TLR7 pathway, TLR8 pathway and TLR9 pathway, or a combination thereof.

30. Use of a therapeutically effective amount of the compound of claim 25, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating an autoimmune disease associated with
- i) TLR7 activity, or
 - ii) TLR7 activity and TLR8 activity, or
 - iii) TLR7 activity and TLR8 activity and TLR9 activity,
- wherein the autoimmune disease is systemic lupus erythematosus, cutaneous lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
31. The compound of claim 1 for use as a medicament.